HYTN Innovations Inc (HYTN) AI Stock Analysis

• Market Cap: C$14.99M
• Dividend Yield: N/A
• Average Volume (3M): 21.46K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.86
• Revenue Growth: 47.86%
• EPS Growth: -225.43%
• Country: CA
• Employees: 7
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Beverages - Alcoholic
• EPS (TTM): >-0.01
• Shares Outstanding: 93,708,110
• 10 Day Avg. Volume: 10,488
• 30 Day Avg. Volume: 21,464
• PEG Ratio: -0.02
• Price to Book (P/B): -114.63
• Price to Sales (P/S): 23.29
• P/FCF Ratio: -24.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 40 Underperform
• Price Target: C$0.00 ▼(-100.00% Downside)

HYTN Innovations Inc. faces significant financial challenges with negative profitability and cash flow, compounded by a weak balance sheet. Technical analysis indicates a bearish trend, and valuation metrics are unattractive due to negative earnings. These factors collectively result in a low overall stock score.

HYTN Innovations Inc Business Overview & Revenue Model

Company Description

HYTN Innovations Inc. engages in the research, production, marketing, distribution, and sale of cannabis products for recreational consumers in Canada. It intends to offer infused sparkling beverages and infused edibles in various flavors. The company is headquartered in Vancouver, Canada.

How the Company Makes Money

HYTN generates revenue through a diversified model that includes direct sales of its proprietary software and hardware products, subscription-based services for ongoing software updates and support, and licensing agreements that allow third parties to use its technologies. Key revenue streams include the sale of communication devices, cloud-based software solutions, and consulting services for businesses looking to implement advanced communication systems. Additionally, strategic partnerships with major telecommunications providers and technology firms enhance HYTN's market reach and provide additional revenue opportunities through joint ventures and collaborative projects.

HYTN Innovations Inc Financial Statement Overview

Summary

HYTN Innovations Inc. is in a difficult financial position with negative profitability and cash flow metrics, coupled with a concerning balance sheet showing negative equity. While there is slight revenue growth, the company faces significant liquidity and solvency risks, necessitating strategic improvements to enhance financial health.

Income Statement

HYTN Innovations Inc. has shown some revenue growth, but profitability remains a concern with negative net income, EBIT, and EBITDA margins. The gross profit margin is slightly positive, indicating potential for future improvement, but the net profit margin remains deeply negative.

Balance Sheet

The company's balance sheet shows a negative equity position, indicating financial instability. The debt-to-equity ratio cannot be calculated due to negative equity, and the equity ratio is also negative, highlighting potential solvency issues.

Cash Flow

HYTN's cash flow statement reveals negative free cash flow and operating cash flow, suggesting cash burn. The company relies heavily on financing activities, which may not be sustainable long-term. There is no free cash flow growth, and the ratios to net income are challenging to assess with negative figures.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	1.28M	851.49K	763.46K	696.36K	0.00	0.00
Gross Profit	784.03K	287.44K	91.85K	121.65K	0.00	-1.12K
EBITDA	-6.39M	-6.26M	-1.45M	-9.88M	-745.51K	-310.99K
Net Income	-6.76M	-6.61M	-2.33M	-17.38M	-959.48K	-311.66K
Balance Sheet
Total Assets	2.21M	2.38M	2.58M	3.79M	2.76M	507.25K
Cash, Cash Equivalents and Short-Term Investments	52.07K	256.58K	187.56K	1.03M	264.06K	271.16K
Total Debt	981.81K	793.56K	919.74K	887.22K	2.58M	41.98K
Total Liabilities	2.94M	2.56M	2.27M	1.71M	2.77M	18.41K
Stockholders Equity	-734.88K	-172.97K	314.72K	2.07M	-8.88K	488.85K
Cash Flow
Free Cash Flow	-915.73K	-804.21K	-1.18M	-2.38M	-1.67M	-409.37K
Operating Cash Flow	-896.81K	-783.36K	-1.18M	-2.16M	-693.52K	-311.08K
Investing Cash Flow	164.59K	162.67K	-4.10K	2.19M	-1.02M	-98.29K
Financing Cash Flow	492.87K	689.71K	346.17K	727.93K	1.80M	700.53K

HYTN Innovations Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HYTN, the sentiment is Negative. The current price of 0.16 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.20, and below the 200-day MA of 0.24, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.48 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:HYTN.

HYTN Innovations Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BR	44 Neutral	C$24.93M	-0.68	-40.08%	―	21.12%	-102.58%
HYTN	40 Underperform	C$14.99M	―	-9999.00%	―	47.86%	-225.43%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%

HYTN Innovations Inc Corporate Events

HYTN Innovations Secures Cannabis Drug Licence, Expanding Pharmaceutical Capabilities

HYTN Innovations Inc. has received a Cannabis Drug Licence (CDL) from Health Canada, enhancing its capabilities to manufacture cannabis-derived pharmaceutical drugs. This positions HYTN among a select group of organizations in Canada authorized for such production, allowing it to expand into the pharmaceutical market. The CDL enables HYTN to support clinical research, pursue drug approvals, and engage in global pharmaceutical supply chains, thereby strengthening its industry positioning. The company’s dual licensing allows it to act as a Contract Development and Manufacturing Organization (CDMO) partner, providing GMP-compliant cannabinoid production and formulation development for clinical-stage biotech and pharmaceutical companies.